Mineo Takei

Summary

Affiliation: Central Research Laboratories
Country: Japan

Publications

  1. ncbi request reprint [Development of polaprezinc research]
    Mineo Takei
    Pharmacological Research, Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Saitama, Japan
    Yakugaku Zasshi 132:271-7. 2012
  2. doi request reprint Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats
    Hiroki Hamano
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya City, Saitama 360 0111, Japan
    Life Sci 85:759-64. 2009
  3. doi request reprint CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells
    Hiroki Kato
    Department of Clinical Research, Zeria Pharmaceutical Co, Ltd, Tokyo, Japan
    Life Sci 89:603-8. 2011
  4. pmc Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice
    Yuki Orikawa
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya shi, Saitama, Japan
    Mol Pain 6:72. 2010
  5. doi request reprint Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach
    Kazuyoshi Yoshii
    Central Research Laboratories, ZERIA Pharmaceutical Corporation, Ltd, Saitama 360 0111, Japan
    J Pharm Sci 100:4965-73. 2011
  6. doi request reprint Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats
    Masanao Kawachi
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya shi, Saitama, Japan
    Eur J Pharmacol 666:218-25. 2011
  7. ncbi request reprint Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain
    Koji Yoshinaga
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya, Saitama 360 0111, Japan
    Biol Pharm Bull 33:244-8. 2010
  8. ncbi request reprint Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells
    Nobuyoshi Kobayashi
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Oshikiri, Kumagaya, Saitama 360 0111, Japan
    Biol Pharm Bull 33:216-22. 2010
  9. ncbi request reprint Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Daisuke Kawasaki
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1, Numagami, Oshikiri, Kumagaya City, Saitama 360 0111, Japan
    Cancer Chemother Pharmacol 61:883-92. 2008
  10. ncbi request reprint Z-100, an Immunomodulatory Extract of Mycobacterium tuberculosis Strain Aoyama B, Prevents Spontaneous Lymphatic Metastasis of B16-BL6 Melanoma
    Takayuki Horii
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd
    Biol Pharm Bull 37:642-7. 2014

Collaborators

Detail Information

Publications14

  1. ncbi request reprint [Development of polaprezinc research]
    Mineo Takei
    Pharmacological Research, Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Saitama, Japan
    Yakugaku Zasshi 132:271-7. 2012
    ..In this review, we primarily make reference to our own data on the pharmacological action of polaprezinc on taste disorders and introduce recent research on the effects of polaprezinc in treating other diseases...
  2. doi request reprint Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats
    Hiroki Hamano
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya City, Saitama 360 0111, Japan
    Life Sci 85:759-64. 2009
    ..To clarify the mechanism underlying the effect of polaprezinc on hypogeusia, we investigated the uptake of polaprezinc by the tongue in rats...
  3. doi request reprint CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells
    Hiroki Kato
    Department of Clinical Research, Zeria Pharmaceutical Co, Ltd, Tokyo, Japan
    Life Sci 89:603-8. 2011
    ..In this study, we investigated the role of the CCK-2/gastrin signaling pathway on gemcitabine-induced VEGF expression in PANC-1 human pancreatic carcinoma cells...
  4. pmc Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice
    Yuki Orikawa
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya shi, Saitama, Japan
    Mol Pain 6:72. 2010
    ....
  5. doi request reprint Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach
    Kazuyoshi Yoshii
    Central Research Laboratories, ZERIA Pharmaceutical Corporation, Ltd, Saitama 360 0111, Japan
    J Pharm Sci 100:4965-73. 2011
    ..8) at steady state was markedly higher than unity. Taken together, these results suggest that carrier-mediated concentrative uptake processes play an important role in the distribution of acotiamide to the stomach but not skeletal muscle...
  6. doi request reprint Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats
    Masanao Kawachi
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya shi, Saitama, Japan
    Eur J Pharmacol 666:218-25. 2011
    ....
  7. ncbi request reprint Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain
    Koji Yoshinaga
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Numagami, Oshikiri, Kumagaya, Saitama 360 0111, Japan
    Biol Pharm Bull 33:244-8. 2010
    ..Z-360 is expected to become a useful drug for the pancreatic cancer with analgesic effects as well as the prolongation of survival...
  8. ncbi request reprint Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells
    Nobuyoshi Kobayashi
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1 Oshikiri, Kumagaya, Saitama 360 0111, Japan
    Biol Pharm Bull 33:216-22. 2010
    ..These results help to explain how Z-360 prolongs survival when used in combination with gemcitabine...
  9. ncbi request reprint Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro
    Daisuke Kawasaki
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, 2512 1, Numagami, Oshikiri, Kumagaya City, Saitama 360 0111, Japan
    Cancer Chemother Pharmacol 61:883-92. 2008
    ....
  10. ncbi request reprint Z-100, an Immunomodulatory Extract of Mycobacterium tuberculosis Strain Aoyama B, Prevents Spontaneous Lymphatic Metastasis of B16-BL6 Melanoma
    Takayuki Horii
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd
    Biol Pharm Bull 37:642-7. 2014
    ..The combination of low dose Z-100 and irradiation also inhibited spontaneous lymph node metastases. These findings suggest that Z-100 may be beneficial in preventing lymphatic metastasis by enhancing the immune response. ..
  11. doi request reprint Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride
    Yugo Matsunaga
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Saitama, Japan
    J Pharmacol Exp Ther 336:791-800. 2011
    ..Acotiamide thus represents a beneficial new drug for the treatment of functional dyspepsia involving gastric motility dysfunction, with differences from other prokinetic agents...
  12. ncbi request reprint Effect of polaprezinc on taste disorders in zinc-deficient rats
    Hiroki Hamano
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Saitama, Japan
    Biofactors 28:185-93. 2006
    ..In conclusion, polaprezinc had a therapeutic effect in a rat model of abnormal taste sensation. Its mechanism of action was suggested to involve improvement of the decrease in taste bud cell proliferation caused by zinc deficiency...
  13. doi request reprint Concentration dependence of 5-aminosalicylic acid pharmacological actions in intestinal mucosa after oral administration of a pH-dependent formulation
    Masamichi Hirayama
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Saitama, Japan
    Mol Pharm 8:1083-9. 2011
    ..We also report the release characteristics of Asacol and the targeted delivery of 5-ASA to affected sites in IBD patients...
  14. ncbi request reprint ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles
    Yoshihiro Kawabata
    Central Research Laboratories, Zeria Pharmaceutical Co, Ltd, Oshikiri, Kohnan machi, Ohsato gun, Saitama 360 0111, Japan
    Pharm Res 21:467-75. 2004
    ....